Walking Speed After 40: The Longevity Marker You Can Test on Your Own Sidewalk

There is a longevity test that costs nothing, takes about ten seconds, and requires no blood draw. You walk. Four meters, at the pace you would use to cross a parking lot, while someone holds a stopwatch. That is the whole protocol.

For decades, geriatricians have used that measurement as shorthand for how well an older body is holding together. What is newer, and far more interesting for anyone in midlife, is that walking speed after 40 already carries real signal. It is not a number that only goes wrong at 75. By the mid-forties it is quietly tracking muscle, nerve, brain and mitochondrial health all at once, which makes it one of the few whole-body aging markers you can check on your own sidewalk, today, for free.

Here is what the research actually shows, and what it suggests about the cellular machinery underneath your stride.

Why a Walking Test Measures More Than Legs

Walking feels automatic, which is exactly why it is such a useful measurement. A normal stride is an integrated task. It requires force from the hip and calf muscles, intact knees and ankles, vestibular and visual input to stay upright, peripheral nerve conduction fast enough to coordinate the sequence, cardiorespiratory capacity to sustain the effort, and enough executive function to hold a chosen pace while your attention is elsewhere.

Any weak link in that chain shows up the same way: you slow down. That is why gait speed behaves less like a leg test and more like a composite index of how many systems are quietly running below specification. It is also why it is hard to fake. You can brace for a grip strength test. You cannot really brace for the way you walk.

There is a second reason it matters, and it is metabolic. Walking faster costs more adenosine triphosphate per minute, and most of that is produced by oxidative phosphorylation inside the mitochondria of slow-twitch muscle fibers. Pace is, in part, a readout of energy supply.

The Survival Numbers That Made Researchers Pay Attention

The study that moved gait speed from a research curiosity to a clinical vital sign pooled individual data from nine cohort studies: 34,485 community-dwelling adults aged 65 and older, followed for six to 21 years [1]. Mean gait speed was 0.92 meters per second.

Every additional 0.1 m/s of speed was associated with roughly a 12 percent lower hazard of death, and the relationship held across the entire range rather than only at the slow end. At age 75, predicted ten-year survival ranged from 19 percent to 87 percent in men and 35 percent to 91 percent in women depending on nothing but how fast they walked. Strikingly, a model using only age, sex and gait speed predicted survival about as well as a model built from chronic conditions, smoking history, blood pressure, body mass index and prior hospitalizations.

A later pooled analysis of 27,220 older adults found the same pattern for disability rather than death: slower baseline gait speed predicted who would lose the ability to perform daily activities [3]. These are observational findings in older cohorts, so they describe association rather than cause. But the consistency across tens of thousands of people is hard to dismiss.

What Walking Speed After 40 Says About Biological Aging

The more provocative data come from midlife. The Dunedin study has followed a representative New Zealand birth cohort since 1972, and researchers measured gait speed in 904 participants at age 45 [2]. Mean usual pace was 1.30 m/s, dual-task pace was 1.16 m/s, and maximum pace was 1.99 m/s.

Slower walkers at 45 were not simply less athletic. They showed accelerated biological aging across multiple organ systems, older-looking faces, smaller total brain volume, more cortical thinning, smaller cortical surface area and more white matter hyperintensities on MRI. They also had weaker grip, poorer balance, worse visual-motor coordination and lower midlife IQ. Most unsettling, poor neurocognitive function measured as early as age three predicted slower walking four decades later.

"Adults' gait speed is associated with more than geriatric functional status; it is also associated with midlife aging and lifelong brain health." [2]

The usual caveats apply. This is one cohort, largely of European ancestry, and the design cannot prove that slow walking causes anything. What it does establish is that by your mid-forties, pace is already carrying information about the whole organism, not just the legs.

How to Measure Your Own Pace

The research protocol is simple enough to replicate on a quiet stretch of sidewalk or hallway.

Mark a four-meter course, then add about two meters of lead-in space before the start line so you are already at steady pace when timing begins. Walk at your normal, comfortable, going-somewhere speed. Have someone start the stopwatch as your lead foot crosses the first mark and stop it at the second. Run three trials and average them. Divide four by your time in seconds to get meters per second.

For context, the Dunedin midlife average was 1.30 m/s, which works out to about 3.1 seconds over four meters. In older adults, clinicians often flag speeds below roughly 0.8 m/s as a marker of elevated risk. It is also worth running a dual-task version: count backwards from 100 by threes while you walk, and note how much you slow. A large gap between your usual and dual-task pace points more toward the cognitive and attentional side of the equation than the muscular one.

Treat this as a tracking tool, not a diagnosis. Measure once a quarter and watch the direction of travel. A number that drifts downward over two years is far more meaningful than any single result.

The Mitochondrial Layer Under Your Stride

If pace partly reflects energy supply, it is worth looking at what limits that supply. Nicotinamide adenine dinucleotide, or NAD+, sits at the center of the process. It is the electron carrier required for glycolysis, for flux through the citric acid cycle and for the electron transport chain itself. It is also the substrate consumed by sirtuins and PARP enzymes during stress and DNA repair.

NAD+ availability falls with age and metabolic stress in several tissues, while consumption by enzymes such as CD38 and the PARPs rises. The field is genuinely unsettled on how large those tissue-level declines are and how well precursor supplementation translates into function, and a 2024 review in Nature Reviews Molecular Cell Biology lays out those open questions carefully [7].

Two human trials are relevant to muscle specifically. In a randomized trial in older men, three weeks of oral nicotinamide riboside raised the NAD+ metabolome inside skeletal muscle itself, shifted the muscle transcriptome and lowered several circulating inflammatory cytokines [5]. Separately, ten weeks of nicotinamide mononucleotide in prediabetic postmenopausal women improved skeletal muscle insulin sensitivity and insulin signaling, although the trial enrolled only 25 participants [6]. Studies suggest the mechanism is real in human muscle. They do not yet tell us how much faster anyone walks because of it.

What the NAD+ Walking Trials Actually Showed

One trial went straight at the functional question. The NICE trial randomized 90 people with peripheral artery disease, a group with high oxidative stress, impaired mitochondrial activity and genuinely poor walking performance, to six months of nicotinamide riboside with or without resveratrol, or placebo [4]. The primary outcome was six-minute walk distance.

Participants on nicotinamide riboside gained 7.0 meters while the placebo group lost 10.6 meters, a between-group difference of 17.6 meters. Among participants who actually took at least 75 percent of their assigned pills, nicotinamide riboside improved six-minute walk by 31.0 meters. Resveratrol added nothing on top. The authors were explicit that a larger trial is needed to confirm the result.

Read that honestly and it is encouraging rather than conclusive. The population had established arterial disease, not healthy midlife physiology. The effect was modest. A broader review of NAD+ boosting compounds in humans reached a similar verdict: precursors reliably raise blood NAD+ and are well tolerated, while functional and performance outcomes remain inconsistent across trials [8].

That is the reasoning behind physician-supervised NAD+ protocols such as the one offered through RenuviaRX, where injectable delivery is used to bypass first-pass metabolism and achieve more predictable exposure. Patients frequently report steadier daily energy and easier recovery from training, though individual response varies and no supplement treats or cures disease.

What Reliably Moves the Number

The levers with the strongest evidence behind them are unglamorous, and they stack well with anything else you are doing.

Load your legs. Progressive resistance work twice a week, built around chair stands, step-ups, split squats and loaded carries, addresses the force production that sets your ceiling. Then train the ceiling directly: short bouts of deliberately brisk walking, 30 to 60 seconds at a pace you would use to catch a train, teach the nervous system to recruit quickly rather than simply sustain.

Eat enough protein, in the range of 1.2 to 1.6 grams per kilogram of body weight daily for most active adults in midlife, spread across meals rather than loaded into dinner. Add balance work, since instability quietly caps pace in people whose muscles are perfectly adequate. Get vision corrected and sleep protected, because both feed directly into the attentional side of gait. And if your pace is slipping alongside numbness, tingling or unexplained fatigue, ask your physician about B12 and homocysteine status, since peripheral nerve conduction is part of the chain too.

The Takeaway

Walking speed after 40 is one of the rare longevity markers that is free, repeatable, and responsive to effort. It integrates muscle, nerve, brain and mitochondrial function into a single number you can measure in a hallway, and the midlife data suggest it is already telling you something about how the whole system is aging.

If your number is drifting, treat it as information rather than a verdict. Load your legs, protect your sleep, eat enough protein, and pay attention to the cellular energy supply that makes all of it possible. If you want to explore whether a physician-supervised NAD+ protocol fits into your own longevity plan, the RenuviaRX medical team reviews each intake individually with a board-certified physician.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. doi:10.1001/jama.2010.1923
2. Rasmussen LJH, Caspi A, Ambler A, et al. Association of neurocognitive and physical function with gait speed in midlife. JAMA Network Open. 2019;2(10):e1913123. doi:10.1001/jamanetworkopen.2019.13123
3. Perera S, Patel KV, Rosano C, et al. Gait speed predicts incident disability: a pooled analysis. The Journals of Gerontology: Series A. 2016;71(1):63-71. doi:10.1093/gerona/glv126
4. McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. 2024;15(1):5046. doi:10.1038/s41467-024-49092-5
5. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717-1728.e6. doi:10.1016/j.celrep.2019.07.043
6. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985
7. Migaud ME, Ziegler M, Baur JA. Regulation of and challenges in targeting NAD+ metabolism. Nature Reviews Molecular Cell Biology. 2024;25(10):822-840. doi:10.1038/s41580-024-00752-w
8. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. The Journals of Gerontology: Series A. 2023;78(12):2435-2448. doi:10.1093/gerona/glad106